Free Drug Monitoring

Abstract

Drugs are bound to various serum proteins in different degrees varying from 0% protein binding to 99% protein binding, but only unbound or free drug is pharmacologically active. Although free drug concentration can be estimated from total concentration knowing the extent of protein binding of a particular drug, for strongly bound drugs (more than 80% bound to serum protein), prediction of free level is not always possible. Conditions such as uremia, liver disease and hypoalbuminemia can lead to significant increases in free drug resulting in drug toxicity although the total drug concentration may be within the established therapeutic range. Drug–drug interactions are another major cause for disproportionate increases in free drug concentrations. Currently, free drug concentrations of anticonvulsants such as phenytoin, carbamazepine and valproic acid are widely measured in clinical laboratories. Newer drugs such as mycophenolic acid mofetil and certain protease inhibitors are also considered as good candidates for monitoring free drug concentration.

Key Concepts:

  • There are rationales for monitoring free drug concentration only for drugs that are strongly bound to serum proteins (80% or more).

  • Why free concentrations of phenytoin, valproic acid and carbamazepine are frequently monitored in certain patient population?

  • There is a need for monitoring free drug levels in uremia due to impaired protein binding of drugs as well as displacement of certain drugs from protein binding by ceratin uremic toxins.

  • There is a need for monitoring free drug concentrations in hepatic diseases due to impaired protein binding of certain drugs.

  • There is a need for monitoring free drug concentration in patients with hypoalbuminemia and critically ill patients due to elevated concentrations of free levels of drugs secondary to impaired protein binding.

  • There is a need for monitoring free drug concentrations in pregnancy due to change in protein binding and various other factors that affect clearance of certain drugs.

  • There is a need for monitoring free drug concentrations in AIDS patients due to impaired protein binding and probable drug–drug interactions.

  • Future candidates for monitoring free drugs include mycophenolic acid and protease inhibitors because these drugs are strongly bound to albumin and also have narrow therapeutic index.

  • Special case of monitoring free drug concentrations is digoxin, which is only 25% bound to serum proteins, but monitoring free digoxin in patients being treated with Digibind or taking certain herbal supplements is helpful to get clinically meaningful results.

Keywords: free drugs; anticonvulsants; immunosuppressant; protein binding; clinical utility

Figure 1.

Chemical structures of frequently monitored free drugs: phenytoin, carbamazepine and valproic acid.

Figure 2.

Chemical structures of bufalin, oleandrin and digoxin.

close

References

Anderson PL, Brundage RC, Bushman L et al. (2000) Indinavir plasma protein binding in HIV‐1 infected adults. AIDS 14: 2293–2297.

Arimori K, Nanko M, Otagiri M and Uekama K (1984) Effect of penicillins on binding of phenytoin to plasma proteins in vitro and in vivo. Biopharmaceutics & Drug Disposition 5: 219–227.

Barrail A, Tiec CL, Paci‐Bonaventure S et al. (2006) Determination of amprenavir total and unbound concentrations in plasma by high performance liquid chromatography and ultrafiltration. Therapeutic Drug Monitoring 28: 89–94.

Blum RA, Schentag JJ, Gardner MJ and Wilner KD (1995) The effect of tenidap sodium on the disposition and plasma protein binding of phenytoin in healthy male volunteers. British Journal of Clinical Pharmacology 39(suppl. I): 35S–38S.

Boffito M, Hoggard PG, Lindup WE et al. (2004) Lopinavir protein binding in vivo through 12‐hour dosing interval. Therapeutic Drug Monitoring 26: 35–39.

Booker HE and Darcey B (1973) Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication. Epilepsia 2: 177–184.

Burger D, Meenhorst PL, Mulder JW et al. (1994) Therapeutic drug monitoring of phenytoin in patients with the acquired immunodeficiency syndrome. Therapeutic Drug Monitoring 16: 616–620.

Burt M, Anderson DC, Kloss J and Apple FS (2000) Evidence based implementation of free phenytoin therapeutic drug monitoring. Clinical Chemistry 46: 1132–1135.

Butler JM and Begg EJ (2008) Free drug metabolic clearance in elderly people. Clinical Pharmacokinetics 47: 297–321.

Chow L, Johnson M, Wells A and Dasgupta A (2003) Effect of the traditional Chinese medicine Chan Su, Lu‐Shen‐Wan, DanShen and Asian ginseng on serum digoxin measurement by Tina‐Quant (Roche) and Synchron LX system (Beckman) digoxin immunoassays. Journal of Clinical Laboratory Analysis 17: 22–27.

Dasgupta A, Biddle D, Wells A and Datta P (2000) Positive and negative interference of Chinese medicine Chan Su in serum digoxin measurement: elimination of interference using a monoclonal chemiluminescent digoxin assay or monitoring free digoxin. American Journal of Clinical Pathology 114: 174–179.

Dasgupta A and Datta P (2004) Rapid detection of oleander poisoning using digoxin immunoassay: comparison of five assays. Therapeutic Drug Monitoring 26: 658–663.

Dasgupta A, Dennen DA, Dean R and McLawhon RW (1991) Displacement of phenytoin from serum protein carriers by antibiotics: studies with ceftriaxone, nafcillin and sulfamethoxazole. Clinical Chemistry 37: 98–100.

Dasgupta A and Emerson L (1996) Interaction of valproic acid with nonsteroidal anti‐inflammatory drugs mefenamic acid and fenoprofen in normal and uremic sera: lack of interaction in uremic sera due to the presence of endogenous factors. Therapeutic Drug Monitoring 18: 654–659.

Dasgupta A and Malik S (1994) Fast atom bombardment mass spectrometric determination of the molecular weight range of uremic compounds that displace phenytoin from protein binding: absence of midmolecular uremic toxins. American Journal of Nephrology 14: 162–168.

Dasgupta A and McLemore J (1998) Elevated free phenytoin and free valproic acid concentrations in sera of patients infected with human immunodeficiency virus. Therapeutic Drug Monitoring 20: 63–67.

Dasgupta A, Risin SA, Reyes M and Actor JK (2008) Rapid detection of oleander poisoning by Digoxin III, a new digoxin immunoassay: impact on serum digoxin measurement. American Journal of Clinical Pathology 129: 548–553.

Dasgupta A, Saffer H, Wells A and Datta P (2002) Bidirectional (positive/negative) interference of spironolactone, canrenone and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin. Journal of Clinical Laboratory Analysis 16: 172–177.

Ghuman J, Zunszain P, Petitpas I et al. (2005) Structural basis of drug‐binding specificity of human serum albumin. Journal of Molecular Biology 353: 38–52.

Gidal BE, Collins DM and Beinlich BR (1993) Apparent valproic acid neurotoxicity in a hypoalbuminemic patient. Annals of Pharmacotherapy 27: 32–35.

Haroldson JA, Kramer LE, Wolff DL and Lake KD (2000) Elevated free fractions of valproic acid in a heart transplant patient with hypoalbuminemia. Annals of Pharmacotherapy 34: 183–187.

Hooper W, Dubetz D, Bochner F et al. (1975) Plasma protein binding of carbamazepine. Clinical Pharmacology and Therapeutics 17: 433–440.

Kemper EM, van Khan HJ, Speelman P et al. (2007) Severe phenytoin intoxication in patients with hypoalbuminemia. Nederlands tijdschrift voor geneeskunde 151: 138–141. [Article in Dutch].

Klotz U, Rapp T and Muller WA (1978) Disposition of VPA in patients with liver disease. European Journal of Clinical Pharmacology 13: 55–60.

Ko R, Greenwald M, Loscutoff S et al. (1996) Lethal ingestion of Chinese tea containing Chan SU. Western Journal of Medicine 164: 71–75.

Lenn NJ and Robertson M (1992) Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy. Neurology 42: 988–990.

McMillin GA, Owen WE, Lambert TL et al. (2002) Comparable effects of DIGIBIND and DigiFab in thirteen digoxin immunoassays. Clinical Chemistry 48: 1580–1584.

Meinardi H, van der Kleijn E and Meijer JWA (1982) Absorption and distribution of anti‐epileptic drugs. Epilepsia 23: 23–26.

Monaghan MS, Marx MA, Olsen KM, Turner PD and Bergman KL (2001) Correlation and prediction of phenytoin using standard laboratory parameters in patients after renal transplantation. Therapeutic Drug Monitoring 23: 263–267.

Otagiri M (2005) A molecular functional study on the interactions of drugs with plasma proteins [Review]. Drug Metabolism and Pharmacokinetics 20: 309–323.

Panesar NS (1992) Bufalin and unidentified substances in traditional Chinese medicine cross‐react in commercial digoxin assay. Clinical Chemistry 38: 2155–2156.

Pennell PB (2003) Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 61(suppl. 2): S35–S42.

Pospisil J and Perlik F (1992) Binding parameters of phenytoin during monotherapy and polytherapy. International Journal of Clinical Pharmacology, Therapy, and Toxicology 30: 24–28.

Prabhakar S and Bhatia R (2003) Management of agitation and convulsions in hepatic encephalopathy. Indian Journal of Gastroenterology 22(suppl. 2): S54–S58.

Sandyk R (1982) Phenytoin toxicity induced by interaction with ibuprofen. South African Medical Journal 62: 592.

Soldin SJ (1999) Free drug measurements when and why? An overview. Archives of Pathology & Laboratory Medicine 123: 822–823.

Steimer W, Muller C and Eber B (2002) Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone and other steroids. Clinical Chemistry 48: 507–516.

Takamura N, Maruyama T and Otagiri M (1997) Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia. Clinical Chemistry 43: 2274–2280.

Toler SM, Wilkerson MA, Porter WH, Smith AJ and Chandler MH (1990) Severe phenytoin intoxication as a result of altered protein binding in AIDS. DICP: The Annals of Pharmacotherapy 24: 698–700.

Tomson T (2005) Gender aspect of pharmacokinetics of new and old AEDs; pregnancy and breast feeding. Therapeutic Drug Monitoring 27: 718–721.

Tomson T, Lindbom U, Ekqvist B et al. (1994) Epilepsy and pregnancy: a prospective study on seizure control in relation to free and total concentrations of carbamazepine and phenytoin. Epilepsia 35: 122–130.

Tsanaclis LM, Allen J, Perucca E, Routledge PA and Richens A (1984) Effect of valproate on free plasma phenytoin concentrations. British Journal of Clinical Pharmacology 18: 17–20.

Van Hest RM, van Gelder T, Vulto AG et al. (2009) Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. Clinical Pharmacokinetics 48: 463–476.

Von Winckelmann SL, Spriet I and Willems L (2008) Therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacotherapy 28: 1391–1400.

Watson I, Potter J, Yatscoff R et al. (1997) Therapeutic Drug Monitoring [Editorial] 19: 125.

Wolf GK, McClain CD, Zurakoski D et al. (2006) Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children. Pediatric Critical Care Medicine 7: 434–439.

Wright DF and Begg EJ (2010) The apparent clearance of free phenytoin in elderly vs younger adults. British Journal of Clinical Pharmacology 70: 132–138.

Yerby MS, Friel PN and McCormick K (1992) Antiepileptic drug disposition during pregnancy. Neurology 42(suppl. 5): 12–16.

Zielmann S, Mielck F, Kahl R et al. (1994) A rational basis for the measurement of free phenytoin concentration in critically ill trauma patients. Therapeutic Drug Monitoring 16: 139–144.

Further Reading

Gallop K (2010) Phenytoin use and efficacy in the ED [review]. Emergency Medicine Australasia 22: 108–118.

Gustafsson SS, Vrang L, Terelius Y and Danielson UH (2010) Quantification of interactions between drug leads and serum proteins by use of “binding efficiency”. Analytical Biochemistry. October 28 [e‐pub ahead of print].

Langman LJ (2007) The use of oral fluid for therapeutic drug management: clinical and forensic toxicology. Annals of the New York Academy of Sciences 1098: 145–166.

Morris RG, Hones TE, Wicks FA and Rogers NM (2008) Measuring the unbound concentration fials to resolve analytical interferences in digoxin immunoassays. Therapeutic Drug Monitoring 30: 548–552.

Ueshima S, Aiba T, Makita T et al. (2008) Characterization of non‐linear relationship between total and unbound serum concentrations of valproic acid in epileptic children. Journal of Clinical Pharmacy and Therapeutics 33: 31–38.

Vial Y, Tod M, Hornecker M et al. (2010) In vitro influence of fatty acids and bilirubin on binding of mycophenolic acid to human serum albumin. Journal of Pharmaceutical and Biomedical Analysis. September 29 [e‐pub ahead of print].

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Dasgupta, Amitava(Feb 2011) Free Drug Monitoring. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0023211]